Posted by & filed under Company Analysis, Growth & Valuation.

Description: Mark Baum, Imprimis Pharmaceuticals CEO, explains how his company is able to make a Daraprim drug alternative more accessible to patients.

Source: – video report

Date: Feb 04, 2016


Questions for discussion:

  • What is the basis for criticizing the pharmaceutical industry?
  • Do you believe there will be greater legal and regulatory reaction to these revelations?
  • How should investors respond to these events?

Leave a Reply

Your email address will not be published. Required fields are marked *